About Sol-Gel Technologies Ltd. - Ordinary Shares (SLGL)
Sol-Gel Technologies Ltd is a biotechnology company focused on developing and commercializing innovative treatments for skin diseases, particularly dermatological conditions. The company utilizes its proprietary technologies to create a range of topical products, including formulations for acne and other skin disorders. By leveraging its expertise in drug delivery systems and materials science, Sol-Gel aims to improve patients' quality of life through effective and safe therapies that address unmet medical needs in the dermatology sector. Read More
Sol-Gel Technologies (NASDAQ:SLGL) outlined its development and commercialization plans for SGT-610, a topical patidegib treatment being studied to reduce new basal cell carcinomas (BCCs) in patients with Gorlin syndrome, a rare inherited disorder associated with recurrent skin cancers and other man
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 5.28% on the day to $3.99.
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at $3.21 on Friday.
The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them.
